Webinar
The First 5 Months: Practical Implications of the JCA
In this learning session, “The First 5 Months: Practical Implications of the JCA,” our expert discusses the early experiences and insights gained from the implementation of the Joint Clinical Assessment (JCA) under the EU HTA regulation. Ann-Sophie Kuschel shares practical implications for stakeholders involved in the development and commercialization of cell and gene therapies, highlighting the unique challenges and considerations relevant to this process.
Explore and how the JCA impacts the landscape for advanced therapies in Europe to prepare to navigate this evolving regulatory environment.
Speaker:
- Ann-Sophie Kuschel - Principal at Vintura, a Cencora company
Fill out the form to watch the session
Pardot Form
Connect with our cell and gene experts
Our tailored solutions address the unique challenges of advanced therapies, from early discovery through to patient delivery, ensuring that innovative treatments reach those who need them most. Connect with our expert team today to learn how Cencora can support your product’s journey.
